Skip to main content

Abstract

Despite advances in schizophrenia treatment, symptom relapses and rehospitalizations impede recovery for many people and are a principal driver of the high cost of care. Technology-delivered or technology-enhanced treatment may be a cost-effective way to provide flexible, personalized evidence-based treatments directly to people in their homes and communities. However, evidence for the safety, acceptability, and efficacy of such interventions is only now being established. The authors of this Open Forum describe a novel, technology-based approach to prevent relapse after a hospitalization for psychosis, the Health Technology Program (HTP), which they developed. HTP provides in-person relapse prevention planning that directs use of tailored, technology-based treatment based on cognitive-behavioral therapy for psychosis, family psychoeducation for schizophrenia, and prescriber decision support through a Web-based program that solicits information from clients at every visit. Technology-based treatments are delivered through smartphones and computers.
Despite advances in schizophrenia treatment, symptom relapses and rehospitalizations impede recovery for many people and are the principal driver of the high cost of care (1). Relapse prevention planning, cognitive-behavioral therapy for psychosis (CBTp), family psychoeducation, and pharmacotherapy are evidence-based approaches to treating schizophrenia that reduce symptoms, distress, relapses, and hospitalizations. However, most of these services are not available in outpatient mental health treatment settings, leaving people vulnerable to relapse in the period immediately following a hospitalization. More cost-effective interventions are needed to improve access to effective treatments that can prevent relapses and hospitalizations, as well as their disruptive effects on people’s lives.
Technology-delivered or technology-enhanced treatment allows more accessible, convenient, and flexible delivery of evidence-based treatments in the home and community and can function as a clinician extender, enabling more treatment with less clinician time. Furthermore, by facilitating people’s use of relapse prevention strategies, such interventions may prevent costly hospitalizations. Individuals may vary in their preferences for or response to various interventions; thus access to multiple types of interventions could optimize outcomes.
We developed a novel, multicomponent, technology-based approach to relapse prevention. The six-month Health Technology Program (HTP) provides in-person, individualized relapse prevention planning that directs use of technology-based treatments delivered on smartphones and computers and provides a Web-based prescriber decision support program. Interventions are delivered within extensively tested, user-friendly interfaces. A trained case manager guides the individual through the program, provides coaching, monitors the individual, and works in tandem with a psychiatric prescriber. HTP is designed for delivery in outpatient community mental health settings that provide services to people with schizophrenia.
Below we describe the rationale and approach for the HTP relapse prevention program and each component. We then discuss the potential benefits and pitfalls of technology-facilitated treatment and the need for further research.

Technology-Enhanced Relapse Prevention

A strong body of evidence supports the effectiveness of relapse prevention planning for people with schizophrenia (2). In HTP, the case manager works with the client to develop and implement a personalized relapse prevention plan built on the stress-vulnerability coping model (3). Relapse prevention skills are taught by the case manager, supported by smartphone- and computer-based treatments, and coordinated with the prescriber and tailored pharmacological treatment. The case manager and client collaboratively develop a personal plan by exploring reasons for preventing relapses; reviewing the last relapse; identifying early warning signs, triggers, and preventive strategies; making a plan to monitor and respond to early warning signs; identifying specific coping strategies; and seeking input from natural supports (for example, family). A brief manual and worksheets support the process of creating, learning, and sharing the plan with other service providers and supportive persons, as well as using the plan to guide deployment of technology-based treatments.
The HTP program has three phases that are individualized on the basis of the person’s symptoms and preferences. In phase 1 (one to two months), the case manager and client develop the plan. Clients are linked with the prescriber for medication and offered the FOCUS smartphone intervention with medication adherence support and one or two of five other coping modules on the basis of their symptoms and early warning signs. Clients who have regular contact with family or other supportive people decide whether to involve them in their plan and whether to use the family psychoeducation-based tool (see below).
In phase 2 (two to three months), the relapse prevention plan is implemented with use of additional technology-delivered family psychoeducation, CBTp, and reminders and symptom management strategies, as described below. The plan is modified as needed, with the case manager assisting and troubleshooting the use of the technology-based interventions. Use of interventions can change: clients may use one or more tools for a period of time and then switch to different ones. In phase 3 (one to two months), the relapse prevention plan is modified one last time if needed, the case manager helps the client plan his or her transition to usual clinical services, and the use of the technology tools ends.

Smartphone Intervention for Schizophrenia

FOCUS is a smartphone system that was developed in collaboration with clinicians and clients. Its five modules are designed to enhance coping with symptoms, mood, or sleep problems; improve social situations; and encourage medication use (4). The case manager and client select FOCUS content on the basis of persistent symptoms or sources of stress that increase risk of relapse.
FOCUS uses system-generated audio prompts and on-demand resources (visual aids, photos, and cartoons) and written text to teach evidence-based coping strategies through interactive assessments, exercises, and suggestions that clients can access as they encounter challenges in their daily lives. FOCUS transmits clients’ responses to self-assessments and intervention utilization data to a secure server (for example, daily ratings of clinical status and missed assessments). The case manager views this information on a Web-based dashboard and provides live consultation or technical troubleshooting as needed. Thus FOCUS integrates automated, on-demand, and live support options in one approach. Field testing indicated that FOCUS is feasible, acceptable, and usable and suggested that it reduces symptoms and distress for people with schizophrenia (5).

Computerized CBTp

There is strong evidence for the effectiveness of CBTp for reducing psychotic and other symptoms in schizophrenia (6). Two Web-based CBTp skills programs, “Coping With Voices” and “Coping With Paranoia,” incorporate traditional elements of CBTp, including goal setting, psychoeducation, normalization of symptoms, coping strategy enhancement, cognitive restructuring, and home practice. The programs help clients develop strategies to cope with voices and paranoia to prevent symptoms from escalating to a relapse. The programs are interactive and self-paced. They include animated tutorials, exercises, and games; personal symptom and goals tracking; and independent skills practice worksheets. Participants progress through modules, cumulatively building skills. Case managers introduce clients to the programs, link the content to clients’ relapse prevention plans, track their progress through a Web-based dashboard, and provide ongoing support. A pilot study of the “Coping With Voices” program found high levels of engagement, program completion, and satisfaction, as well as symptom reductions, among users (7).

The Daily Support Website

The Daily Support Website (DSW) uses both Web- and phone-based resources to support illness management and recovery for persons with schizophrenia and their supporters. Based on empirically validated approaches to family psychoeducation (8), the program provides education about schizophrenia, teaches problem-solving skills, and facilitates social support for clients and their relatives and other supporters to reduce family stress and improve coping in order to prevent relapses. The prototype DSW was developed with extensive user testing to ensure usability and comprehension (9), and a one-year study demonstrated improved symptoms among users compared with a control group (10).
The DSW includes Web-based group forums, a library of educational resources, an “ask the expert” service, a “frequently asked questions” library, and a news feed. The forums (one each for clients and supporters and one for both) are facilitated by therapists who promote and emphasize discussions on solving problems, alleviating stress, and increasing social support. The DSW also offers phone resources via encrypted text message or an interactive voice response system. The early-warning-signs resource queries clients regarding signs of relapse and suggests coping strategies. A reminder system provides tailored prompts for medications and cues for events such as medical appointments. HTP case managers utilize the DSW dashboard to create user accounts, designate phone functions, and monitor client usage so that case managers can support their use of the tool.

Prescriber Decision Support System

Pharmacotherapy guidelines recommend monthly meetings between prescribers and clients to prevent symptom relapses related to medication nonadherence or inefficacy. These guidelines were implemented in HTP by using a computerized clinical decision support system with a measurement-based care approach, modeled on a system developed for the RAISE-ETP study (Recovery After an Initial Schizophrenia Episode Early Treatment Program), which was funded by the National Institute of Mental Health (11). All HTP prescribers and clients accessed the program from a secure Web site. Prior to each prescriber visit, the client enters information into the system by answering a series of simple questions about symptoms, side effects, and treatment preferences. The prescriber then reviews these data, which guide the in-person evaluation session. The system includes recommendations about evidence-based medication strategies that inform joint client-prescriber decision making, as well as suggestions for other HTP interventions (for example, “Coping With Voices” for clients with auditory hallucinations).

Discussion

Given the high burden of poorly managed schizophrenia and the limited resources to treat these individuals, technology-facilitated treatment may be an efficient and accessible alternative to conventional approaches. However, research on the translation of evidence-based treatments for schizophrenia into technology-facilitated interventions—and evaluation of whether they are safe, acceptable, effective, and cost-effective—has made less progress than research on interventions for other mental health conditions, such as depression (12). Nevertheless, technology has infused people’s daily lives, including those with schizophrenia, as indicated by their high rates of mobile device usage and their interest in using personal technology to facilitate mental health services (13), which suggests that such approaches may be appealing.
Certain technology program design features may be particularly key for this population. For example, therapist-assisted approaches provide safety assessment and monitoring support for adoption, and they may be more effective than independently used Internet interventions (12). Thus we chose a case manager–facilitated model for HTP. In addition, to address the concern that technology-facilitated interventions may not be usable by people with schizophrenia (14), HTP interventions were tailored with unique features for people with cognitive impairments (15).
Although previous work suggested that single technology–delivered interventions were both acceptable and effective in this group (5,7,10), a case manager–facilitated, multicomponent approach has yet to be evaluated. We are currently evaluating the safety, acceptability, and efficacy of HTP for reducing readmission among outpatients with schizophrenia who have been recently discharged from a hospital. Future reports will describe the research design of this study and describe clinical outcomes, user satisfaction, and cost savings from this new model of technology-facilitated care for people with schizophrenia.

References

1.
Ascher-Svanum H, Zhu B, Faries DE, et al: The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 10:2, 2010
2.
Mueser KT, Corrigan PW, Hilton D, et al: Illness management and recovery: a review of the research. Psychiatric Services 53:1272–1284, 2002
3.
Nuechterlein KH, Dawson ME: A heuristic vulnerability/stress model of schizophrenic episodes. Schizophrenia Bulletin 10:300–312, 1984
4.
Ben-Zeev D, Kaiser SM, Brenner CJ, et al: Development and usability testing of FOCUS: a smartphone system for self-management of schizophrenia. Psychiatric Rehabilitation Journal 36:289–296, 2013
5.
Ben-Zeev D, Brenner CJ, Begale M, et al: Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia. Schizophrenia Bulletin 40:1244–1253, 2014
6.
Burns AM, Erickson DH, Brenner CA: Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review. Psychiatric Services 65:874–880, 2014
7.
Gottlieb JD, Romeo KH, Penn DL, et al: Web-based cognitive-behavioral therapy for auditory hallucinations in persons with psychosis: a pilot study. Schizophrenia Research 145:82–87, 2013
8.
Anderson CM, Reiss DJ, Hogarty GE: Schizophrenia and the Family: A Practitioner’s Guide to Psychoeducation and Management. New York, Guilford, 1986
9.
Rotondi AJ, Sinkule J, Haas GL, et al: Designing websites for persons with cognitive deficits: design and usability of a psychoeducational intervention for persons with severe mental illness. Psychological Services 4:202–224, 2007
10.
Rotondi AJ, Anderson CM, Haas GL, et al: Web-based psychoeducational intervention for persons with schizophrenia and their supporters: one-year outcomes. Psychiatric Services 61:1099–1105, 2010
11.
Mueser KT, Penn DL, Addington J, et al: The NAVIGATE program for first-episode psychosis: rationale, overview, and description of psychosocial components. Psychiatric Services 66:680–690, 2015
12.
Saddichha S, Al-Desouki M, Lamia A, et al: Online interventions for depression and anxiety: a systematic review. Health Psychology and Behavioral Medicine 2:841–881, 2014
13.
Ben-Zeev D, Davis KE, Kaiser S, et al: Mobile technologies among people with serious mental illness: opportunities for future services. Administration and Policy in Mental Health 40:340–343, 2013
14.
Brunette MF, Ferron JC, Devitt T, et al: Do smoking cessation websites meet the needs of smokers with severe mental illnesses? Health Education Research 27:183–190, 2012
15.
Rotondi AJ, Eack SM, Hanusa BH, et al: Critical design elements of e-health applications for users with severe mental illness: singular focus, simple architecture, prominent contents, explicit navigation, and inclusive hyperlinks. Schizophrenia Bulletin 41:440–448, 2015

Information & Authors

Information

Published In

Go to Psychiatric Services
Go to Psychiatric Services

Cover: Fame Weathervane, by E.G. Washburne and Company, circa 1890. Copper and zinc with gold leaf. American Folk Art Museum, Long Island City, New York. Gift of Ralph Esmerian, accession number 2005.8.62. Photo credit: Gavin Ashworth.

Psychiatric Services
Pages: 444 - 447
PubMed: 26725297

History

Received: 2 July 2015
Revision received: 8 November 2015
Accepted: 20 November 2015
Published online: 4 January 2016
Published in print: April 01, 2016

Authors

Details

Mary F. Brunette, M.D.
Dr. Brunette and Dr. Ben-Zeev are with the Department of Psychiatry, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire (e-mail: [email protected]). They are also with the Center for Technology and Behavioral Health, Dartmouth Psychiatric Research Center, Lebanon, New Hampshire. Dr. Rotondi is with the Clinical and Translational Sciences Institute, Department of Critical Care Medicine, University of Pittsburgh, and with the Mental Illness Research, Education and Clinical Center, Department of Veterans Affairs Medical Center, Pittsburgh, Pennsylvania. Dr. Gottlieb and Dr. Mueser are with the Center for Psychiatric Rehabilitation and with the Department of Occupational Therapy, Boston University. Dr. Robinson and Dr. Kane are with the Feinstein Institute for Medical Research, Manhasset, New York, and with the Department of Psychiatry and Molecular Medicine, Hofstra North Shore–LIJ School of Medicine, Hempstead, New York. Dr. Achtyes is with Cherry Street and the Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids. Ms. Gingerich is an independent consultant and trainer in Narberth, Pennsylvania. Ms. Marcy is with Northwell Health, Great Neck, New York, and Vanguard Research Group, Glen Oaks, New York. Dr. Schooler is with the Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, and with the Zucker Hillside Hospital, Glen Oaks, New York. Dr. Meyer-Kalos is with the Department of Social Work, Minnesota Center for Chemical and Mental Health, St. Paul.
Armando J. Rotondi, Ph.D.
Dr. Brunette and Dr. Ben-Zeev are with the Department of Psychiatry, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire (e-mail: [email protected]). They are also with the Center for Technology and Behavioral Health, Dartmouth Psychiatric Research Center, Lebanon, New Hampshire. Dr. Rotondi is with the Clinical and Translational Sciences Institute, Department of Critical Care Medicine, University of Pittsburgh, and with the Mental Illness Research, Education and Clinical Center, Department of Veterans Affairs Medical Center, Pittsburgh, Pennsylvania. Dr. Gottlieb and Dr. Mueser are with the Center for Psychiatric Rehabilitation and with the Department of Occupational Therapy, Boston University. Dr. Robinson and Dr. Kane are with the Feinstein Institute for Medical Research, Manhasset, New York, and with the Department of Psychiatry and Molecular Medicine, Hofstra North Shore–LIJ School of Medicine, Hempstead, New York. Dr. Achtyes is with Cherry Street and the Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids. Ms. Gingerich is an independent consultant and trainer in Narberth, Pennsylvania. Ms. Marcy is with Northwell Health, Great Neck, New York, and Vanguard Research Group, Glen Oaks, New York. Dr. Schooler is with the Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, and with the Zucker Hillside Hospital, Glen Oaks, New York. Dr. Meyer-Kalos is with the Department of Social Work, Minnesota Center for Chemical and Mental Health, St. Paul.
Dror Ben-Zeev, Ph.D.
Dr. Brunette and Dr. Ben-Zeev are with the Department of Psychiatry, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire (e-mail: [email protected]). They are also with the Center for Technology and Behavioral Health, Dartmouth Psychiatric Research Center, Lebanon, New Hampshire. Dr. Rotondi is with the Clinical and Translational Sciences Institute, Department of Critical Care Medicine, University of Pittsburgh, and with the Mental Illness Research, Education and Clinical Center, Department of Veterans Affairs Medical Center, Pittsburgh, Pennsylvania. Dr. Gottlieb and Dr. Mueser are with the Center for Psychiatric Rehabilitation and with the Department of Occupational Therapy, Boston University. Dr. Robinson and Dr. Kane are with the Feinstein Institute for Medical Research, Manhasset, New York, and with the Department of Psychiatry and Molecular Medicine, Hofstra North Shore–LIJ School of Medicine, Hempstead, New York. Dr. Achtyes is with Cherry Street and the Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids. Ms. Gingerich is an independent consultant and trainer in Narberth, Pennsylvania. Ms. Marcy is with Northwell Health, Great Neck, New York, and Vanguard Research Group, Glen Oaks, New York. Dr. Schooler is with the Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, and with the Zucker Hillside Hospital, Glen Oaks, New York. Dr. Meyer-Kalos is with the Department of Social Work, Minnesota Center for Chemical and Mental Health, St. Paul.
Jennifer D. Gottlieb, Ph.D.
Dr. Brunette and Dr. Ben-Zeev are with the Department of Psychiatry, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire (e-mail: [email protected]). They are also with the Center for Technology and Behavioral Health, Dartmouth Psychiatric Research Center, Lebanon, New Hampshire. Dr. Rotondi is with the Clinical and Translational Sciences Institute, Department of Critical Care Medicine, University of Pittsburgh, and with the Mental Illness Research, Education and Clinical Center, Department of Veterans Affairs Medical Center, Pittsburgh, Pennsylvania. Dr. Gottlieb and Dr. Mueser are with the Center for Psychiatric Rehabilitation and with the Department of Occupational Therapy, Boston University. Dr. Robinson and Dr. Kane are with the Feinstein Institute for Medical Research, Manhasset, New York, and with the Department of Psychiatry and Molecular Medicine, Hofstra North Shore–LIJ School of Medicine, Hempstead, New York. Dr. Achtyes is with Cherry Street and the Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids. Ms. Gingerich is an independent consultant and trainer in Narberth, Pennsylvania. Ms. Marcy is with Northwell Health, Great Neck, New York, and Vanguard Research Group, Glen Oaks, New York. Dr. Schooler is with the Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, and with the Zucker Hillside Hospital, Glen Oaks, New York. Dr. Meyer-Kalos is with the Department of Social Work, Minnesota Center for Chemical and Mental Health, St. Paul.
Kim T. Mueser, Ph.D.
Dr. Brunette and Dr. Ben-Zeev are with the Department of Psychiatry, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire (e-mail: [email protected]). They are also with the Center for Technology and Behavioral Health, Dartmouth Psychiatric Research Center, Lebanon, New Hampshire. Dr. Rotondi is with the Clinical and Translational Sciences Institute, Department of Critical Care Medicine, University of Pittsburgh, and with the Mental Illness Research, Education and Clinical Center, Department of Veterans Affairs Medical Center, Pittsburgh, Pennsylvania. Dr. Gottlieb and Dr. Mueser are with the Center for Psychiatric Rehabilitation and with the Department of Occupational Therapy, Boston University. Dr. Robinson and Dr. Kane are with the Feinstein Institute for Medical Research, Manhasset, New York, and with the Department of Psychiatry and Molecular Medicine, Hofstra North Shore–LIJ School of Medicine, Hempstead, New York. Dr. Achtyes is with Cherry Street and the Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids. Ms. Gingerich is an independent consultant and trainer in Narberth, Pennsylvania. Ms. Marcy is with Northwell Health, Great Neck, New York, and Vanguard Research Group, Glen Oaks, New York. Dr. Schooler is with the Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, and with the Zucker Hillside Hospital, Glen Oaks, New York. Dr. Meyer-Kalos is with the Department of Social Work, Minnesota Center for Chemical and Mental Health, St. Paul.
Delbert G. Robinson, M.D.
Dr. Brunette and Dr. Ben-Zeev are with the Department of Psychiatry, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire (e-mail: [email protected]). They are also with the Center for Technology and Behavioral Health, Dartmouth Psychiatric Research Center, Lebanon, New Hampshire. Dr. Rotondi is with the Clinical and Translational Sciences Institute, Department of Critical Care Medicine, University of Pittsburgh, and with the Mental Illness Research, Education and Clinical Center, Department of Veterans Affairs Medical Center, Pittsburgh, Pennsylvania. Dr. Gottlieb and Dr. Mueser are with the Center for Psychiatric Rehabilitation and with the Department of Occupational Therapy, Boston University. Dr. Robinson and Dr. Kane are with the Feinstein Institute for Medical Research, Manhasset, New York, and with the Department of Psychiatry and Molecular Medicine, Hofstra North Shore–LIJ School of Medicine, Hempstead, New York. Dr. Achtyes is with Cherry Street and the Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids. Ms. Gingerich is an independent consultant and trainer in Narberth, Pennsylvania. Ms. Marcy is with Northwell Health, Great Neck, New York, and Vanguard Research Group, Glen Oaks, New York. Dr. Schooler is with the Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, and with the Zucker Hillside Hospital, Glen Oaks, New York. Dr. Meyer-Kalos is with the Department of Social Work, Minnesota Center for Chemical and Mental Health, St. Paul.
Eric D. Achtyes, M.D., M.S.
Dr. Brunette and Dr. Ben-Zeev are with the Department of Psychiatry, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire (e-mail: [email protected]). They are also with the Center for Technology and Behavioral Health, Dartmouth Psychiatric Research Center, Lebanon, New Hampshire. Dr. Rotondi is with the Clinical and Translational Sciences Institute, Department of Critical Care Medicine, University of Pittsburgh, and with the Mental Illness Research, Education and Clinical Center, Department of Veterans Affairs Medical Center, Pittsburgh, Pennsylvania. Dr. Gottlieb and Dr. Mueser are with the Center for Psychiatric Rehabilitation and with the Department of Occupational Therapy, Boston University. Dr. Robinson and Dr. Kane are with the Feinstein Institute for Medical Research, Manhasset, New York, and with the Department of Psychiatry and Molecular Medicine, Hofstra North Shore–LIJ School of Medicine, Hempstead, New York. Dr. Achtyes is with Cherry Street and the Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids. Ms. Gingerich is an independent consultant and trainer in Narberth, Pennsylvania. Ms. Marcy is with Northwell Health, Great Neck, New York, and Vanguard Research Group, Glen Oaks, New York. Dr. Schooler is with the Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, and with the Zucker Hillside Hospital, Glen Oaks, New York. Dr. Meyer-Kalos is with the Department of Social Work, Minnesota Center for Chemical and Mental Health, St. Paul.
Susan Gingerich, M.S.W.
Dr. Brunette and Dr. Ben-Zeev are with the Department of Psychiatry, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire (e-mail: [email protected]). They are also with the Center for Technology and Behavioral Health, Dartmouth Psychiatric Research Center, Lebanon, New Hampshire. Dr. Rotondi is with the Clinical and Translational Sciences Institute, Department of Critical Care Medicine, University of Pittsburgh, and with the Mental Illness Research, Education and Clinical Center, Department of Veterans Affairs Medical Center, Pittsburgh, Pennsylvania. Dr. Gottlieb and Dr. Mueser are with the Center for Psychiatric Rehabilitation and with the Department of Occupational Therapy, Boston University. Dr. Robinson and Dr. Kane are with the Feinstein Institute for Medical Research, Manhasset, New York, and with the Department of Psychiatry and Molecular Medicine, Hofstra North Shore–LIJ School of Medicine, Hempstead, New York. Dr. Achtyes is with Cherry Street and the Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids. Ms. Gingerich is an independent consultant and trainer in Narberth, Pennsylvania. Ms. Marcy is with Northwell Health, Great Neck, New York, and Vanguard Research Group, Glen Oaks, New York. Dr. Schooler is with the Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, and with the Zucker Hillside Hospital, Glen Oaks, New York. Dr. Meyer-Kalos is with the Department of Social Work, Minnesota Center for Chemical and Mental Health, St. Paul.
Patricia Marcy, B.S.N.
Dr. Brunette and Dr. Ben-Zeev are with the Department of Psychiatry, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire (e-mail: [email protected]). They are also with the Center for Technology and Behavioral Health, Dartmouth Psychiatric Research Center, Lebanon, New Hampshire. Dr. Rotondi is with the Clinical and Translational Sciences Institute, Department of Critical Care Medicine, University of Pittsburgh, and with the Mental Illness Research, Education and Clinical Center, Department of Veterans Affairs Medical Center, Pittsburgh, Pennsylvania. Dr. Gottlieb and Dr. Mueser are with the Center for Psychiatric Rehabilitation and with the Department of Occupational Therapy, Boston University. Dr. Robinson and Dr. Kane are with the Feinstein Institute for Medical Research, Manhasset, New York, and with the Department of Psychiatry and Molecular Medicine, Hofstra North Shore–LIJ School of Medicine, Hempstead, New York. Dr. Achtyes is with Cherry Street and the Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids. Ms. Gingerich is an independent consultant and trainer in Narberth, Pennsylvania. Ms. Marcy is with Northwell Health, Great Neck, New York, and Vanguard Research Group, Glen Oaks, New York. Dr. Schooler is with the Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, and with the Zucker Hillside Hospital, Glen Oaks, New York. Dr. Meyer-Kalos is with the Department of Social Work, Minnesota Center for Chemical and Mental Health, St. Paul.
Nina R. Schooler, Ph.D.
Dr. Brunette and Dr. Ben-Zeev are with the Department of Psychiatry, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire (e-mail: [email protected]). They are also with the Center for Technology and Behavioral Health, Dartmouth Psychiatric Research Center, Lebanon, New Hampshire. Dr. Rotondi is with the Clinical and Translational Sciences Institute, Department of Critical Care Medicine, University of Pittsburgh, and with the Mental Illness Research, Education and Clinical Center, Department of Veterans Affairs Medical Center, Pittsburgh, Pennsylvania. Dr. Gottlieb and Dr. Mueser are with the Center for Psychiatric Rehabilitation and with the Department of Occupational Therapy, Boston University. Dr. Robinson and Dr. Kane are with the Feinstein Institute for Medical Research, Manhasset, New York, and with the Department of Psychiatry and Molecular Medicine, Hofstra North Shore–LIJ School of Medicine, Hempstead, New York. Dr. Achtyes is with Cherry Street and the Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids. Ms. Gingerich is an independent consultant and trainer in Narberth, Pennsylvania. Ms. Marcy is with Northwell Health, Great Neck, New York, and Vanguard Research Group, Glen Oaks, New York. Dr. Schooler is with the Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, and with the Zucker Hillside Hospital, Glen Oaks, New York. Dr. Meyer-Kalos is with the Department of Social Work, Minnesota Center for Chemical and Mental Health, St. Paul.
Piper Meyer-Kalos, Ph.D.
Dr. Brunette and Dr. Ben-Zeev are with the Department of Psychiatry, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire (e-mail: [email protected]). They are also with the Center for Technology and Behavioral Health, Dartmouth Psychiatric Research Center, Lebanon, New Hampshire. Dr. Rotondi is with the Clinical and Translational Sciences Institute, Department of Critical Care Medicine, University of Pittsburgh, and with the Mental Illness Research, Education and Clinical Center, Department of Veterans Affairs Medical Center, Pittsburgh, Pennsylvania. Dr. Gottlieb and Dr. Mueser are with the Center for Psychiatric Rehabilitation and with the Department of Occupational Therapy, Boston University. Dr. Robinson and Dr. Kane are with the Feinstein Institute for Medical Research, Manhasset, New York, and with the Department of Psychiatry and Molecular Medicine, Hofstra North Shore–LIJ School of Medicine, Hempstead, New York. Dr. Achtyes is with Cherry Street and the Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids. Ms. Gingerich is an independent consultant and trainer in Narberth, Pennsylvania. Ms. Marcy is with Northwell Health, Great Neck, New York, and Vanguard Research Group, Glen Oaks, New York. Dr. Schooler is with the Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, and with the Zucker Hillside Hospital, Glen Oaks, New York. Dr. Meyer-Kalos is with the Department of Social Work, Minnesota Center for Chemical and Mental Health, St. Paul.
John M. Kane, M.D.
Dr. Brunette and Dr. Ben-Zeev are with the Department of Psychiatry, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire (e-mail: [email protected]). They are also with the Center for Technology and Behavioral Health, Dartmouth Psychiatric Research Center, Lebanon, New Hampshire. Dr. Rotondi is with the Clinical and Translational Sciences Institute, Department of Critical Care Medicine, University of Pittsburgh, and with the Mental Illness Research, Education and Clinical Center, Department of Veterans Affairs Medical Center, Pittsburgh, Pennsylvania. Dr. Gottlieb and Dr. Mueser are with the Center for Psychiatric Rehabilitation and with the Department of Occupational Therapy, Boston University. Dr. Robinson and Dr. Kane are with the Feinstein Institute for Medical Research, Manhasset, New York, and with the Department of Psychiatry and Molecular Medicine, Hofstra North Shore–LIJ School of Medicine, Hempstead, New York. Dr. Achtyes is with Cherry Street and the Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids. Ms. Gingerich is an independent consultant and trainer in Narberth, Pennsylvania. Ms. Marcy is with Northwell Health, Great Neck, New York, and Vanguard Research Group, Glen Oaks, New York. Dr. Schooler is with the Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, and with the Zucker Hillside Hospital, Glen Oaks, New York. Dr. Meyer-Kalos is with the Department of Social Work, Minnesota Center for Chemical and Mental Health, St. Paul.

Funding Information

Center for Medicaid and Medicare Innovation: 1C1CMS331052
Support for research on the Health Technology Program was provided by the Center for Medicaid and Medicare Innovation.Dr. Brunette receives research support from Alkermes. Dr. Ben-Zeev has an intervention content licensing agreement with Pear Therapeutics. Dr. Robinson has been a consultant or received grants from Asubio, Bristol-Myers Squibb, Janssen, Otsuka, and Shire. Dr. Achtyes receives research support from AssurEx, Avinar, Janssen, Novartis, Otsuka, Pfizer, Pine Rest Foundation, Priority Health, and Vanguard Research Group and serves on advisory panels for Roche and Vanguard Research Group. Ms. Marcy is a stockholder in Pfizer. Dr. Schooler has served on advisory boards for Alkermes, Forum (formerly EnVivo), and Sunovion. Dr. Kane has been a consultant for or has received honoraria from Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest, Genentech, H. Lundbeck, Intracellular Therapeutics, Janssen Pharmaceutica, Johnson and Johnson, Otsuka, Reviva, Roche, Sunovion, and Teva and is a shareholder in MedAvante, Inc., and Vanguard Research Group. The other authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Psychiatric Services

PPV Articles - Psychiatric Services

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share